143 related articles for article (PubMed ID: 32769428)
1. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases.
Malpica A; Euscher ED; Marques-Piubelli ML; Ferrufino-Schmidt MC; Miranda RN; Sams R; Royal RE; Raghav KPS; Fournier KF; Ramalingam P
Am J Surg Pathol; 2021 Jan; 45(1):45-58. PubMed ID: 32769428
[TBL] [Abstract][Full Text] [Related]
2. Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases.
Malpica A; Euscher ED; Marques-Piubelli ML; Miranda RN; Fournier KF; Raghav KP; Ramalingam P
Int J Gynecol Pathol; 2022 Jan; 41(1):59-67. PubMed ID: 33577225
[TBL] [Abstract][Full Text] [Related]
3. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases.
Malpica A; Sant'Ambrogio S; Deavers MT; Silva EG
Am J Surg Pathol; 2012 Jan; 36(1):117-27. PubMed ID: 22024662
[TBL] [Abstract][Full Text] [Related]
4. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
5. Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases.
Malpica A; Euscher ED; Marques-Piubelli ML; Miranda RN; Raghav KP; Fournier KF; Ramalingam P
Am J Surg Pathol; 2022 Oct; 46(10):1352-1363. PubMed ID: 35713639
[TBL] [Abstract][Full Text] [Related]
6. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Averous G; Chevallier A; Laverriere MH; Villa I; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J;
Virchows Arch; 2021 Nov; 479(5):927-936. PubMed ID: 34169365
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
Xing D; Banet N; Sharma R; Vang R; Ronnett BM; Illei PB
Hum Pathol; 2018 Feb; 72():160-166. PubMed ID: 29241740
[TBL] [Abstract][Full Text] [Related]
8. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.
Nonaka D; Kusamura S; Baratti D; Casali P; Cabras AD; Younan R; Rosai J; Deraco M
Cancer; 2005 Nov; 104(10):2181-8. PubMed ID: 16206294
[TBL] [Abstract][Full Text] [Related]
9. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
Chapel DB; Schulte JJ; Absenger G; Attanoos R; Brcic L; Butnor KJ; Chirieac L; Churg A; Galateau-Sallé F; Hiroshima K; Hung YP; Kindler H; Krausz T; Marchevsky A; Mino-Kenudson M; Mueller J; Nabeshima K; Turaga K; Walts AE; Husain AN
Mod Pathol; 2021 Feb; 34(2):380-395. PubMed ID: 33060816
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
11. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
12. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years.
Scalabre A; Philippe-Chomette P; Passot G; Orbach D; Elias D; Corradini N; Brugières L; Msika S; Leclair MD; Joseph S; Brigand C; Becmeur F; Soler C; Pezet D; Gagniere J; Glehen O; Sarnacki S
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286576
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
15. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
[TBL] [Abstract][Full Text] [Related]
16. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
Orbach D; André N; Brecht IB; López Almaraz R; Ben-Ami T; Vermersch S; Carton M; Virgone C; Bisogno G; Schneider DT; Bajciova V; Reguerre Y; Galateau-Salle F; Stachowicz-Stencel T; Dvir R; Rees H; Bien E; Ferrari A; Ben Arush M
Eur J Cancer; 2020 Nov; 140():63-70. PubMed ID: 33049597
[TBL] [Abstract][Full Text] [Related]
17. Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
[TBL] [Abstract][Full Text] [Related]
18. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
Liu S; Staats P; Lee M; Alexander HR; Burke AP
Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
[TBL] [Abstract][Full Text] [Related]
19. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
20. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
